Mind Medicine MindMed Inc (MNMD) Quote

you act like a two year old

stop

Lots of douchebags in life

WGAFlying F?

Unbelievable! You’re the one with his panties in a wad.

Go ahead and call me some more names. It’s all you got, Mr. Cool and Collected! LMFAO!

Phase 3 starts soon, loser. Better strap in and tighten up your diapers. Your chicken tendies fund is about to go up if you even have shares.

This is a private web forum. There is no free speech protections here. Your comments can be altered and/or deleted, as well as your account can be removed. This is not a designated public forum. Learn something.

That is absolutely false. It's a micro-dose medication that is taken OUTSIDE of any psychiatric or doctor setting, like taking a Prozac. You are such a blatant basher shortie that it's kind of funny.

Not much risk for me. I bought my shares in summer of 2020. And phase 3 with Breakthrough Designation means 80% or better that MM120 gets approved. You better sell all your shares tomorrow at the bell. Too much risk for you though, it seems.

Yeah, he’s supposed to have me on ignore yet he responds to me every time. Then he gets mad when I quote him from 10 months ago…

Countdown to $40 billion buyout: 8 months and counting down lololol

Who made you the thread monitor?

Absolutly no one

Why are you so afraid of discussion? You know free speech!

If you are so sure "you know what you hold"

Why are you here?

Mind med will be required to have = human trip monitors,to guide and observe Patients while they are on their trip=

If they get a conditional approval.

This guy need therapy, so much so

There is a lot of risk here. The truth makes you mad, huh?

LMAO at you, Jack!

I see the loser shorts still plague this board. Entering phase three with the FDA's blessing is not a long shot. They have more of a chance of FDA approval at this point than non-approval. Get. A. Clue. Losers.

I know the uber longs here don’t believe I’m a long. I think I’ve been a long here a lot longer than most. Seriously, after all the pumping I just feel like anyone new to this stock doing due diligence might need a dose of reality.

Could this turn out to be successful? Absolutely! It can be hugely successful. But this is a developmental biotech. The risks here are real and there’s always going to be bigger chance of failure due to bad financing, running out of money, trial failure, government intervention, etc.

These attacks started last December when Jack said we would get bought out for 30-40 billion dollars in 12 to 18 months. I joked and said “Yeah, that or another reverse split!”

The Uber longs lost their mind! Jack called me names and said he was going to put me on ignore. I guess he couldn’t stand missing out on my input because he answers all my posts. lol

I went through the reverse split just a couple of years ago and reinvested more just to watch it seemingly dwindle away everyday.

This stock is down another 25% in the less than 2 months since the last earnings report and has been severely diluted twice this year, once right before the ER. These are danger signals and I’m going to mention here. I will get called bad names but I think it needs to be mentioned since all we get here is nonstop pumping!

Good luck to all longs, but just know there are no slam dunks in this level of investing. Only invest what you can afford to lose.

You can always sell your shares and wash your hands of MindMed. No one is forcing you to stay. And if you've done so already, why are you here?

They sure can. And many are expressing support of new medications such as MM120. Get. A. Clue.

Odds at this stage of clinical trials, with great results thus far and a Breakthrough Therapy Designation, and with MindMed's backing and cash supply, are probably 80% or better. And if FDA approved, a $40B buyout would be a steal. What part are you having trouble understanding? Legitimately curious how someone could be this obtuse about a psyche medication that could potentially be prescribed to hundreds of millions of people worldwide. And it's not a one-time treatment. It would be a long-term treatment, like anti-depressants. Many, many sales to each patient.

Get. A. Clue.

Thanks for that answer

I fell bad for Torrence the jeanyus

he don't even gut 1/2 a brain

Hey jeanyus

Freedom of speech is allowed


Of course doctors can give their opinion

Holy smoke s

In truth you are still being facetious. Historically, you are not one of the many kuntz we share these message boards with.

…says the man who now predicts FDA approval is a foregone conclusion with a $30B or $40B buyout and who cannot post without including a personal insult. LOLOL

Wait for good phase 3 results (almost a foregone conclusion) and an FDA approval for a novel ANTI-ANXIETY medication with Breakthrough Therapy Designation. Or you can be a fool and sell. Those of us with even half a brain will accumulate the lows.

…says Jack Torrence who predicts a $40 billion buyout

They can't yet. Because the medication hasn't been FDA approved yet. The only legal administration of this drug currently is in clinical trials. Do you have a single brain cell in your head, bro?

Where are the DR's supporting this treatment if it such a big deal?

I did help you out. Clicking on the press release in question and reading it will give you your answer.

This is a forum where people help each other out occasionally you daft twat.

Most of these articles are misunderstanding this nascent sector completely. Psychedelics need not be "legalized" in order for a non-hallucinogenic micro-dose medication to be FDA approved for patient use OUTSIDE of a therapeutic, doctor-supervised setting. In the same way that cocaine and heroine are illegal, but medical cocaine and medical opioids are not. LSD or MDMA or psilocybin need not be legalized for recreation or even in-patient use for FDA APPROVED MEDICATIONS to make it through the clinical trials process and be allowed to be prescribed for specific conditions. There is a difference and I wish people would stop spouting this stupid legalization bullshit constantly on comments boards and forums like it has anything to do with the clinical trials process. Do you really think MindMed would have initiated all these drug trials if their entire possibility of success relied on changing stagnant federal law? I mean, let's use our heads, people.

Why don't you read the related press releases that are readily available, like everyone else?

Yep, agreed, but I was asking about timelines.

We are in the final stretch here. This might be the best level you get going into Phase 3. Hype will build and soon it will glide up with prospects of approval, commercialization and/or buyout.

Sermo Barometer Finds 94% of Global Mental Healthcare Professionals Are Open to Integrating Psychedelic Treatments Into Their Practices If Legalized

Survey of 400+ healthcare professionals examines familiarity, barriers, training, and misconceptions of psychedelic and dissociative drug treatments

https://www.businesswire.com/news/home/20240924302874/en/Sermo-Barometer-Finds-94-of-Global-Mental-Healthcare-Professionals-Are-Open-to-Integrating-Psychedelic-Treatments-Into-Their-Practices-If-Legalized

September 24, 2024 10:00 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--The 34th Barometer from Sermo, an online physician and provider community and leader in healthcare insights, surveyed 430+ mental healthcare providers around the world, including psychiatrists, general practice physicians, and advanced practice providers, on their sentiments about psychedelic and dissociative drug treatments, finding that 94% would be open to integrating these treatments into their practices if legalized in their countries. Worldwide, there has been growing interest from industry, government, media, and patients in psychedelics for the treatment of mental health conditions. 89% of HCPs surveyed believe that psychedelic medicines have unique therapeutic potential compared to traditional medications in treating patients with significant mental health conditions, such as treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa.

Existing Familiarity with Psychedelics:

HCPs are keeping up with developing research about psychedelics for the treatment of mental health conditions. The majority of surveyed healthcare professionals (67%) were either moderately or extensively familiar with the current clinical research on psychedelic and dissociative drugs. Surveyed psychiatrists had more familiarity (71%) with clinical research than other specialties. Ketamine is the most well-known psychedelic and dissociative drug among surveyed HCPs, with 45% indicating they are extremely or very familiar with its use in treating mental health disorders. This is followed by MDMA at 29%, LSD at 26%, and psilocybin at 25%.

According to one anonymous Sermo U.S. psychiatrist and survey respondent, “Psychedelics may have potential significant benefits but they also carry significant risks. If we are to introduce them as psychiatric treatments there needs to be research on their safety and efficacy. They need to be regulated and safety measures need to be put into place. It's important that the right patients obtain benefit and that people do not abuse them. It's important that they be medically supervised to prevent just anyone from using them. Once enough research has been done, I see them integrating into psychiatric care like esketamine, with strict measures in place.”

Potential Barriers & Practice Integration:

If legalized, HCPs feel there are many barriers to integrating psychedelic and dissociative drug treatments into their practices. Healthcare professionals report needing clinical guidelines (80%), comprehensive training programs (78%), and guidance to legal considerations (60%).

HCPs do not view psychedelic and dissociative drugs as a first-line treatment, with nearly half (45%) of surveyed HCPs citing lack of response to traditional treatments as key criteria to prescribe psychedelic and dissociative drugs to a patient.

Patients are also open to the idea of psychedelic and dissociative drug treatments. 79% of those surveyed report that they noticed increasing patient interest in psychedelics as a treatment option. When asked why they felt patients are more open, the most common answer was a growing acceptance of alternative mental health treatments (64%) and increased media coverage of psychedelics (60%).

Agreement with FDA Decisions Varies by Treatment:

U.S. healthcare professionals aren’t always in agreement with the FDA's decisions. Despite the recent decision not to grant MDMA approval for the treatment of PTSD, 52% of HCPs believe an exception should be made for veterans, who have spent years lobbying for the drug, to receive the treatment. However, 73% agreed with the FDA’s decision to grant LSD-based medications breakthrough status for the treatment of generalized anxiety.

Two U.S. states have already decriminalized psilocybin (magic mushrooms) creating easy access for residents to purchase, possess, and grow them. While many healthcare professionals are open to the future of psychedelics to treat mental health conditions, the majority (61%) do not feel patients should be able to readily access psilocybin without medical intervention for the purposes of treating depression, addiction, and PTSD.

Eye on Ketamine:

52% of surveyed HCPs believe that ketamine is being prescribed “off-label” too often. Two-thirds (67%) of surveyed HCPs believe compounding pharmacies should not be allowed to distribute Ketamine.

This survey was fielded August 28th- September 4th as the 34th edition of Sermo’s ongoing Barometer study. The survey included 431 psychiatrists, general practice physicians, and advanced practice providers who have treated a patient for a mental health condition in the last year from the U.S., Canada, Australia, Germany, Italy, Spain, France, and the UK.

To explore more findings, visit: https://app.sermo.com/barometer

What are the related timelines?

This should go up really nice with the next phase results

Will Mind medicine need professionals to guide thier patients thru their trip?

Or just hand them a prescription? Where the patients will take the entire script at once

for a real LSD experience?

A 2.6% daily change is not a bounce. It's nothing. And this is heading into phase 3 on their main drug with Breakthrough Therapy Designation by the FDA. Bash elsewhere, brainless.

Dead cat bounce here.

Psychedelics and the Future of Anxiety Relief



https://youtu.be/GJq5hO1QtEI

I know that.

Send it in and if you do not qualify, find out what you need to qualify.

Never said I was a scientist or have the credentials to work for the FDA. However, I know what we hold here.

With your knowledge Send in your resume to the FDA
Have a good day.

Bank of New York Mellon Corp Purchases 203,216 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

https://www.marketbeat.com/instant-alerts/nasdaq-mnmd-sec-filing-2024-09-19/

What are you implying?

Stop cooking spaghetti

Big Bucks available:
https://www.usajobs.gov/Search/Results?a=HE36

You are referring to LYCOS... furthermore, the MDMA that MindMed is using is a stereo isomer and also not with therapy but only as a drug.

To add to this their phase 3 dual track study has started for LSD with a patented ODT tablet again really without integrated therapy only for at use support.

The failure of lycos was wide and they didn't do their job right.

Good times ahead.

So I'm seeing the latest news is failed FDA trials. This going to be another scenario like Revive? We all know how that went.

Fireside chat at the 2024 Cantor Global Healthcare Conference with Robert Barrow, and CMO Dan Karlin

https://wsw.com/webcast/cantor22/register.aspx?conf=cantor22&page=mnmd&url=https://wsw.com/webcast/cantor22/mnmd/2081412

More debacle!

More debacle!